TRPV2 and breast carcinoma: Notably, at the 72-hour time point, a reduction in the relative healing area was observed in MCF-7, SK-BR-3, and MDA-MB-231 breast cancer cells transfected with TRPV2 siRNA compared to the control group (Fig. 2I-J).